Carbidopa: a selective Ah receptor modulator (SAhRM).

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• The aryl hydrocarbon receptor (AhR) is an intracellular receptor known to bind environmental toxicants like TCDD.
• AhR activation mediates TCDD toxicity but also interacts with diverse compounds, including health-promoting plant derivatives and anticancer pharmaceuticals.

Purpose of the Study:

• To investigate carbidopa, a Parkinson's disease drug, as a potential aryl hydrocarbon receptor (AhR) ligand.
• To explore the effects of carbidopa on pancreatic cancer cell and tumor growth.

Main Methods:

• Identifying carbidopa as an AhR ligand.
• Assessing the impact of carbidopa on pancreatic cancer cell proliferation.
• Evaluating carbidopa's effect on tumor growth in relevant models.

Main Results:

• Carbidopa was identified as a ligand for the aryl hydrocarbon receptor (AhR).
• Carbidopa demonstrated inhibition of pancreatic cancer cell growth.
• Carbidopa also inhibited pancreatic tumor growth, consistent with other AhR-active compounds.

Conclusions:

• Carbidopa functions as a selective AhR modulator.
• AhR modulation by compounds like carbidopa shows potential for inhibiting carcinogenesis.
• These findings support the clinical applications of AhR-dependent selective modulators in cancer therapy.